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Abstract
Background: Intracranial germinomas (ICG) are uncommon brain neoplasms with extremely rare familial occurrence. Because ICG invades 
the hypothalamus and/or pituitary, endocrine dysfunction is one of the common determinants of these tumours.
We present two brothers with a history of ICG. Patient 1 is a 25-year-old male who suffered from weakness of the right half of his 
body at the age of 18 years. Cranial MRI revealed a mass lesion in the left thalamus. He underwent neurosurgery, and the tumour 
was removed completely. Histopathological (HP) and immunohistochemical analyses verified the diagnosis of pure germinoma. He 
experienced complete remission of the tumour after radiation therapy. At the age of 22 years a diagnosis of isolated growth hormone 
deficiency (IGHD) was established and GH replacement was initiated. Molecular genetic analysis of the tumour tissue detected the 
mutation within exon 2 in KRAS gene. Patient 2 is a 20-year-old man who presented with diabetes insipidus at the age of 12 years. MRI 
detected tumour in the third ventricle and pineal region. After endoscopic tumour biopsy the HP diagnosis was pure germinoma. He 
received chemotherapy followed by radiotherapy and was treated with GH during childhood. At the age of 18 years GH replacement 
was reintroduced. A six-month follow-up during the subsequent two years in both brothers demonstrated the IGF1 normalisation with 
no MRI signs of tumour recurrence. 
Conclusion: To the best of our knowledge, so far only six reports have been published related to familial ICG. The presented two brothers 
are the first report of familial ICG case outside Japan. They have been treated successfully with GH therapy in adulthood. (Endokrynol 
Pol 2018; 69 (5): 612–618)
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Streszczenie
Wstęp: Rozrodczaki wewnątrzczaszkowe (intracranial germinomas, ICG) to rzadkie nowotwory mózgu, a szczególnie rzadko stwierdza się 
ich występowanie rodzinne. W związku z tym, że ICG zajmuje podwzgórze i/lub przysadkę mózgową, zaburzenia endokrynologiczne 
są jednym z najczęstszych wyznaczników obecności tych guzów.
W pracy przedstawiono dwóch braci z ICG. Pacjent 1 to 25-letni mężczyzna, u którego w wieku 18 lat wystąpiło osłabienie mięśni po 
lewej stronie ciała. Badanie metodą rezonansu magnetycznego (MRI) czaszki ujawniło masę w lewym wzgórzu. Chorego poddano 
zabiegowi neurochirurgicznemu, podczas którego guz został całkowicie usunięty. Badania histopatologiczne i immunohistochemiczne 
potwierdziły rozpoznanie czystej postaci rozrodczaka. Po radioterapii nastąpiła całkowita remisja guza. W wieku 22 lat u chorego zdia-
gnozowano izolowany niedobór hormonu wzrostu (isolated growth hormone deficiency, IGHD) i wdrożono terapię zastępczą hormonem 
wzrostu (growth hormone, GH). Genetyczna analiza molekularna tkanki guza wykazała mutację w eksonie 2 w genie KRAS. Pacjent 2 to 
20-letni mężczyzna, u którego w wieku 12 lat stwierdzono moczówkę prostą. W badaniu MRI wykryto guz w okolicy trzeciej komory 
i szyszynki. Po ocenie histopatologicznej materiału pobranego za pomocą biopsji endoskopowej postawiono diagnozę czystego rozrod-
czaka. U chorego zastosowano chemioterapię, a następnie radioterapię, a także podawano GH w okresie dzieciństwa. W wieku 18 lat 
u chorego wznowiono terapię GH. Sześciomiesięczna obserwacja obu braci w następnych 2 latach wykazała normalizację IGF1 przy 
braku objawów nawrotu guza w badaniu MRI. 
Wnioski: Według najlepszej wiedzy autorów dotychczas opublikowano 6 doniesień na temat rodzinnego występowania ICG. Przed-
stawieni w niniejszej pracy bracia są pierwszym opisanym przypadkiem rodzinnego ICG poza Japonią. W okresie dorosłym chorzy są 
leczeni GH z dobrym skutkiem. (Endokrynol Pol 2018; 69 (5): 612–618)
Słowa kluczowe: rozrodczak wewnątrzczaszkowy, występowanie rodzinne, niedoczynność przysadki, terapia zastępcza GH
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Case report
Our patients are two brothers with history of intracra-
nial germinomas (ICG). Their auxological and hormonal 
parameters are shown in Table I. They have a third 
brother, who is healthy. Their father died from malig-
nant melanoma, while their grandfather had diabetes 
insipidus of unknown aetiology. 
Patient 1 is a 25-year-old male who suffered numb-
ness and weakness of the right side of the body for one 
month at age 18 years. Cranial MRI showed an expansive 
process that included part of the brain stem and the left 
thalamus (Figures 1A, B). He underwent neurosurgery, 
and the tumour was removed completely. According 
to histopathological (HP) and immunohistochemical 
analyses, a diagnosis of pure germinoma was established 
(Figures 2A–C). Severe neurological sequelae occurred 
after surgery: central facial nerve paresis, truncal ataxia, 
right-sided hemiparesis, and dysarthria. Radiotherapy 
was performed a month after surgery (total dose 51 Gy). 
He experienced complete remission of the tumour and 
remained recurrence-free for the next four years. At the 
age of 22 years he was investigated by a neuroendo-
crinologist, whereupon a physical examination revealed 
the abovementioned neurological manifestations and 
asthenic constitution. Bone mineral density (BMD) was 
severely decreased (Z score L1–L4 = –3.9), and quality 
of life (QoL) measured by AGHDA questionnaire (Adult 
GH Deficiency Assessment) was poor. GH replacement 
had started four years after the complete remission. 
The GH maintenance dose of 0.3 mg daily has been suf-
ficient for the achievement of IGF1 normalisation. The 
two years of GH replacement therapy improved body 
composition and QoL, while BMD did not change (Table 
II). Cranial and spinal MRI showed no signs of tumour 
recurrence (Figures 1C, D). Genetic analysis of tumour 
tissues confirmed variant within exon 2 in KRAS gene 
(NM_033360.3, c.35G>A, p.G12V) (Figure 2E).
Figure 1A, B. Preoperative MRI of Patient 1 shows tumour in the left thalamus; C, D. MRI of Patient 1, six years after radiotherapy 
and two years of GH replacement, shows no signs of tumour recurrence
Rycina 1A, B.Przedzabiegowe badanie MRI Pacjenta 1 pokazuje guz w lewym wzgórzu; C, D. Badanie MRI Pacjenta 1 wykonane 
sześć lat po radioterapii i dwa lata po rozpoczęciu terapii zastępczej GH. Nie ma żadnych cech nawrotu nowotworu
A B C D
Table I. Auxological and hormonal characteristics of patients
Tabela I. Auksjologiczna i hormonalna charakterystyka 
chorych
Patient 1 Patient 2
Age 25 20
Body height [cm] 176 176
Body weight [kg] 47 71
BMI [kg/m2] 15.2 22.7
Hormones and tumour markers
FT4 (7–18 ng/ml) 20.2 14.5
TSH (0.3–5.5 mU/l) 1.4 3.1
Cortisol (131–642 nmol/l) 354 432
FSH (2.5–15 mU/l) 5.3 1.8
LH (2.5–16 mU/l) 3.6 3.7
Testosterone (2.8–8.0 ng/ml) 5.8 3.6
Growth hormone (0–28.5 mU/l) 1.7 1.5
IGF1 [ng/ml]  
before GH therapy 
on GH therapy
 
117 (116–358) 
160
 
195 (193–731) 
370
PRL (121–545 mU/l) 670 411
ACTH (10–90 ng/l) 38 46
PTH (0–80 ng/l) 35 27
ß HCG (< 0.5 ng/ml) 0.178 0.295
αFP (< 5 ng/ml) 1.1 2.1
Glucagon test
GH peak [mU/l] 1.8 8.3
Cortisol [nmol/l] basal 310……
peak 710
basal 392……
peak 690
ITT-insulin tolerance test
GH peak [mU/l] 6.0
Cortisol [nmol/l] basal 270……
peak 499
PRL [mU/l] basal 421…..
peak 791
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Figure 2A. Haematoxylin and eosin (HE) stain of tumour tissue of Patient 1. Tumour tissue is composed of nests of large polygonal 
cells with distinct cell borders, interspersed with lymphocytes. Tumour cells had ample, clear cytoplasm and centrally positioned, round, 
vesicular nuclei with prominent nucleoli; B, C. Immunohistochemical stain of tumour tissue of Patient 1 demonstrated tumour cells 
positive on CD117 and D2-40, OCT-4 and CK (AE1/AE3), and negative on CD30 and αFP; D. Haematoxylin and eosin (HE) stain 
of tumour tissue of Patient 2. Tumour tissue shows lobules of large cells with abundant, clear cytoplasm and round, vesicular nuclei, 
intermingled with numerous lymphocytes; E. Confirmation of detected variant in KRAS gene in Patient 1 by direct sequencing-missense 
variant noted as rs121913529 (c.35 G>T, p.G12V). Codon GGT coding for amino acid glycine is transformed into codon GTT for 
amino acid valine
Rycina 2A. Barwiony hematoksyliną-eozyną (HE) preparat tkanki guza Pacjenta 1. Guz składa się z gniazd dużych komórek poligonalnych 
w wyraźnymi granicami komórek otoczonych przez limfocyty. Komórki nowotworowe zawierają dużo przejrzystej cytoplazmy oraz 
centralnie umiejscowione okrągłe, pęcherzykowate jądro z wyraźnym jąderkiem; B, C. Barwienie immunohistochemiczne tkanki guza 
Pacjenta 1. Widoczne komórki nowotworowe z dodatnią reakcją z CD117 i D2-40, OCT-4 and CK (AE1/AE3), a ujemną z CD30 
i αFP; D. Barwiony hematoksyliną-eozyną (HE) preparat tkanki guza Pacjenta 2. Guz jest zbudowany ze zrazików złożonych z dużych 
komórek z dużą ilością przejrzystej cytoplazmy z okrągłym, pęcherzykowatym jądrem, pomiędzy którymi znajdują się liczne limfocyty; 
E. Potwierdzenie wykrytego wariantu w genie KRAS u Pacjenta 1 przez bezpośredni odczyt sekwencji “missense” rs121913529 (c.35 G>T, 
p.G12V). Kodon GGT kodujący glicynę został zamieniony na kodon GTT kodujący walinę
A B C D
E
Table II. DXA measurement of bone mineral density (BMD) 
and body composition in both patients
Tabela II. Pomiar metodą DXA gęstości mineralnej kości 
(BMD, bone mineral density) i składu ciała u obu chorych
DXA Patient 1 Patient 2
Before GH  
2yrs GH  
therapy
Before GH  
2yrs GH  
therapy
Z sc L1-L4 –3.9 –3.8 –1.5 –2.2
Z sc femoral  
neck
–2.9 –3.2 –1.5 –1.4
% Fat 20.2 16.4 26 23.5
FM — fat mass  
[kg]
9.1 7.9 17.1 16.1
LBM — lean body mass 
[kg]
34.5 37.6 45.7 50.3
TBMC — total bone 
mineral content  
[kg]
1.5 1.5 2.1 2.1
Patient 2 is a 20-year-old man, the younger brother 
of Patient 1. At the age of 12 years he started to complain 
of excessive water intake. The diagnosis of diabetes 
insipidus was established and vasopressin therapy was 
started. Two months later, headaches, vomiting, and di-
plopia occurred, which indicated acute hydrocephalus. 
An MRI revealed a tumour in the third brain ventricle 
and pineal region, with hydrocephalus and dilatation 
of both lateral ventricle (Figure 3A, B). A neurosurgeon 
performed endoscopic ventriculocisternostomy and 
tumour biopsy. Histopathology diagnosis was the 
same as those seen in his brother’s tumour — pure 
germinoma (Figure 2D). Immunohistochemistry and 
genotyping could not performed due to the lack of 
an available surgical specimen. The patient received 
chemotherapy followed by radiotherapy (total dose 
55 Gy), after which MRI showed tumour disappear-
ance. His paediatrician included GH replacement from 
12 to 17 years of age. The patient achieved normal body 
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height, and at the age of 18 years he was admitted to 
neuroendocrine department where hormonal evalua-
tion confirmed diabetes insipidus and isolated GHD. 
He had normal BMD, and QoL had decreased. Cranial 
and spinal MRI excluded tumour recurrence. Five years 
after the complete remission, growth hormone sub-
stitution was recommenced. The starting dose of GH 
was 0.4 mg daily, which was the dose of maintenance. 
Close follow-up every six months for two years showed 
IGF1 normalisation, improvement of body composition 
(Table II), and better QoL with no signs of tumour pres-
ence on MRI (Figures 3C, D). 
Genetic analysis — method and result
Genomic DNA was extracted from formalin-fixed, 
paraffin-embedded samples of tumour tissues (FFPE) 
using a QIAmp DNA Mini Kit (Qiagen, Germany) ac-
cording to the manufacturer’s protocol. The patient was 
genetically diagnosed by next-generation sequencing 
(NGS) using the Illumina Clinical-Exome Sequencing 
TruSight One Gene Panel. Annotation and filtering of 
variants were performed using VariantStudio 3.0 Data 
Analysis Software (Illumina, San Diego, CA). After 
detection of the pathogenic variant in the analysed 
patient, we designed specific primers for Sanger se-
quencing in order to confirm the result, using the NGS 
approach. PCR fragments were directly sequenced us-
ing a Big Dye terminator cycle sequencing kit and an 
ABI PRISM 310 automated sequencer (Applied Biosys-
tems Life Technologies, USA). Missense mutation was 
analysed with PolyPhen-2, SIFT, and MutPred software, 
to predict whether an amino acid substitution affects 
protein function. 
In order to determine the genetic basis of Patient 
1 we used TruSight One Gene Panel and generate 
VCF file. We prioritised 21 genes present in the panel 
(AASS, BCORL1, BRAF, CBL, FGFR2, GIMAP8, HRAS, 
JMYD1C, KIT, KRAS, NF1, NRAS, MAPK8, MAPK10, 
PI3K, PTEN, PIK3R2, PTPRB, PDGFRA, RASA1, and 
TRAF6), and detected the variant within exon 2 in the 
KRAS gene (NM_033360.3, c.35G>A, p.G12V). This ge-
netic variant is predicted to be pathogenic according to 
ClinVar and dbSNP, and deleterious and possibly dam-
aging according to Sift and PolyPhen, respectively. The 
result gained using the NGS approach was confirmed 
by Sanger sequencing.
Discussion
Intracranial germ cell tumours (ICGCT) account for 
about 3% of all brain tumours in children younger than 
15 years, usually occuring between 10 and 14 years of 
age. Their incidence is significantly higher in Japan, 
at 15.4%, than in Western Europe, at 3.6% [1]. ICGCT 
generally develops in the midline, most frequently in 
the pineal region and the suprasellar area, and these 
tumours can also occur in the basal ganglia and/or 
thalamus [2]. According to WHO classification there 
are two main histological types of these tumours: pure 
germinoma and non-germinoma, which includes 
embryonal carcinoma, teratoma, yolk sac tumour, and 
choriocarcinoma [3]. The most common are pure ger-
minoma, while about 30% of ICGCT are mixed forms 
of these five histological types. 
We presented two brothers with a history of intrac-
ranial pure germinoma. To our knowledge, only six 
reports describing the phenomenon of familial ICGCT 
have been published so far, three of which related to 
pure germinoma [4–9]. Until recently it was thought 
that these familial tumours occurred only in siblings, 
but a later report described intracranial germinoma 
(ICG) in father and son [9]. All of the described cases 
are Japanese. Whether race or environmental factors are 
associated with the obviously high incidence of familial 
ICG in Japan is unknown. Our patients are Caucasians 
Figure 3A, B. Preoperative MRI of Patient 2 showed tumour in the third ventricle and pineal region, with hydrocephalus and dilatation 
of both lateral ventricles; C, D. MRI of Patient 2, seven years after radiotherapy and chemotherapy and two years of GH replacement, 
shows no signs of tumour recurrence
Rycina 3A, B. Przedzabiegowe badanie MRI Pacjenta 2 z widocznym guzem w okolicy trzeciej komory i szyszynki oraz wodogłowiem 
i poszerzeniem obu komór bocznych; C, D. Badanie MRI Pacjenta 2 wykonane siedem lat po radioterapii i chemoterapii oraz dwa lata 
po rozpoczęciu terapii zastępczej GH. Nie ma żadnych cech nawrotu nowotworu
A B C D
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of Serbian ethnicity. The presence of ICG in one member 
and the development of other suprasellar lesions in first-
degree relatives has been reported. It included three 
family members: a mother with a Rathke’s cleft cyst, one 
daughter who suffered from intracranial germinoma, 
and the other daughter who had a pituitary cyst [10]. 
Recently, a report of pineal region mixed mature 
teratoma and germinoma in two fraternal brothers of 
fraternal triplets has been published [11].
The cell of origin of intracranial GCTs is still contro-
versial, and the molecular mechanism of tumorigenesis 
remains unclear. Because of the scarcity of tissue sam-
ples available, very little basic research had been carried 
out, and the biology of ICG is poorly understood. Since 
the familial ICGCT is mainly observed in siblings within 
the family, it was considered that their inheritance 
might be autosomal recessive [8]. However, a recent 
study has described ICGCT in the father and son, which 
suggests a more complex pattern of inheritance [9]. 
Several candidate genes have been investigated, which 
could be included in the aetiology of these tumours — 
KIT, KRAS, NANOG, NRAS, CCND, BRAF [12]. The 
strongest evidence is that KIT gene mutation results in 
activation of specific ligand stem cell factor (SCF), which 
has a prominent role in cell proliferation in ICGCT via 
mitogen-activated protein kinase (MAPK) pathway [13]. 
Fukushima et al. examined the KIT signalling pathway 
in 65 patients with sporadic ICGCT, of which 30% are 
pure germinoma [14]. While the mutation in KIT gene 
was by far the most frequently presented (40.0%), the 
alterations in RAS genes (KRAS, NRAS, HRAS, RRAS2) 
were collectively the second most common events in 
pure germinoma (20.0%). Similarly, a large study by 
Ishimura et al. demonstrated that mutually exclusive 
mutations of genes involved in the MAPK pathway 
were most common (48.4%), typically in KIT (27.4%) 
and RAS genes (12.2%), followed by those in the PI3K 
pathway (12.9 %), particularly in MTOR (6.5%), among 
the 124 patients with ICGCT [15]. We performed genetic 
analysis in tumour tissue of Patient 1 and confirmed 
a somatic alteration in exon 2 of the KRAS gene, noted 
as rs121913529 (c.35 G>T, p.G12V). For this KRAS mis-
sense pathogenic variant is known to be a common ge-
netic aberration involved in cancerogenesis, which was 
previously reported in colorectal and lung cancer and 
leukaemia [16–18]. A study by Wang et al. reported a sig-
nificant enrichment of novel and rare germline variants 
in JMJD1C, a histone demethylase and coactivator of 
the androgen receptor, among Japanese IGCT patients 
as compared to a non-Japanese cohort [19]. Several 
cases of ICG associated with chromosomal abnormali-
ties have been reported, which include patients with 
Down’s syndrome and Klinefelter syndrome [20, 21]. 
A recently published study showed that pure germino-
mas are characterised by global low DNA methylation, 
a unique epigenetic feature making them distinct from 
all other ICGCT subtypes. The MAPK and/or PI3K 
pathway alterations, global low DNA methylation, and 
chromosomal instability form a triad that contributes 
in the pathogenesis of ICGCT [22]. Due to the rarity 
of familial occurrence of ICG, there is no data in the 
literature of their pathogenesis.
Since ICG affect the region of the pituitary gland 
and the hypothalamus, clinical manifestations of these 
tumours include diabetes insipidus, which is usually the 
first symptom, followed by visual abnormalities, hydro-
cephalus, and hypopituitarism [23]. Hypopituitarism in 
patients with ICG is usually the consequence of radio-
therapy [24]. In addition to radiotherapy, the tumour size, 
the invasion of surrounding structures, and the extent of 
surgery are crucial for pituitary function in these patients. 
GH deficiency is present in 89–95% of ICGCT, in a similar 
percentage as in hypogonadism, while hypothyroidism 
and hypocorticism are present in about 50% of patients 
[25–27]. Our patients had IGHD, and the younger brother 
had suffered from diabetes insipidus, which persisted af-
ter remission. Interestingly, despite the extensive surgery 
in the older brother and high doses of radiotherapy in 
both patients, only IGHD was confirmed in both. Five- 
-year survival after the radiotherapy of pure germinoma 
was over 90%. Cases of relapse of ICG after 14 and 17 
years from radiotherapy have been reported [28–30]. So 
far, the longest described relapse was 23 years from treat-
ment in a female patient treated with multiple hormone 
replacement therapy including GH [31]. 
Growth hormone may enhance cell proliferation 
and tumorigenesis, and therefore, as a replacement 
therapy, it may potentially increase the risk of secondary 
neoplasms (SN) or recurrence of the primary tumour. 
According to the evidence from the long-term follow-up 
of thousands of patients, the GH safety profile remains 
satisfactory [32, 33]. However, a few studies in child-
hood cancer survivors have shown that GH may induce 
a modest increase in the relative risk of occurrence of 
SN, especially in those treated with radiotherapy, and 
that risk declines over time [34, 35]. On the other hand, 
adults with GHD and a history of childhood cancer 
have not demonstrated an increased cancer risk dur-
ing GH replacement. Our two patients with history of 
malignancy in childhood were successfully treated with 
growth hormone as young adults, four and five years 
after complete remission. The two years of GH replace-
ment therapy improved body composition and QoL. On 
the other hand, their BMD did not change (Patient 1), 
but even decreased (Patient 2). The possible reason for 
this outcome is the short period of GH replacement for 
the full expression of its anabolic effect on the bone. 
Since the pathogenesis and genetic backgrounds of 
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familial ICG are unclear, we speculated that familial 
ICG may be more susceptible to relapse than sporadic 
cases. Because of this assumption, we were especially 
careful in making a decision on the introduction of GH 
therapy in the presented patients. 
To our knowledge, this is the first case that describes 
familial intracranial germinoma outside Japan and the 
seventh case reported so far. 
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